Most people buying peptides have never been walked through how one is made, which is a problem, because almost every quality question that matters is decided during manufacture and almost none of it is visible in the finished vial.
A white powder in a glass vial looks identical whether it came out of a registered facility under CGMP or a bench in a warehouse. This is what actually happens between an amino acid and that vial, and where the failure points are.
Two routes to a peptide
Chemical synthesis builds the chain one residue at a time. It is the route for short peptides — most of the wellness market sits here — and it is fast, scalable and completely dependent on process control.
Recombinant expression engineers an organism to produce the peptide biologically, then purifies it out of the broth. It is how insulin and larger therapeutic peptides are made. It is a far bigger capital undertaking, and it brings a different impurity profile: host cell proteins and DNA rather than synthesis by-products.
Everything below is the chemical route, because that is what is in circulation.
Solid-phase synthesis, and why length is the enemy
Solid-phase peptide synthesis anchors the first amino acid to an insoluble resin bead, then repeats a cycle: deprotect the end of the growing chain, couple the next protected amino acid, wash away everything that did not react. Repeat once per residue.
The arithmetic is unforgiving. Suppose each coupling runs at 99% efficiency — respectable. A 15-residue peptide needs fourteen couplings, so the best case is roughly 0.9914, about 87% of chains intact. At a more realistic 98%, it is about 75%. Every percentage point lost per cycle compounds.
The chains that failed do not vanish. They stay in the mixture as:
- Deletion sequences — a residue skipped mid-chain. Nearly the right mass, nearly the right retention time, and biologically not the same molecule.
- Truncated sequences — synthesis stalled and stopped short.
- Epimers — a stereocentre flipped during coupling. Same mass exactly. A mass spectrometer alone will not tell you.
- Adducts — protecting groups or scavengers that stayed attached.
This is why “we tested it by mass spec and it matched” is a weaker statement than it sounds. Matching mass rules out some failures and is blind to others.
Cleavage, and the counterion nobody mentions
When the chain is complete it is cleaved from the resin and stripped of side-chain protecting groups, usually with a trifluoroacetic acid cocktail plus scavengers to mop up reactive fragments.
The peptide comes out of that process as a TFA salt. That matters for two reasons. TFA is not a desirable counterion in a product intended for administration and is a known confounder in cell-based work, so converting to a more appropriate salt such as acetate is a deliberate extra step — one a cost-driven supplier can simply skip. And the counterion is part of the mass in the vial.
Purification, and what “99% pure” is measuring
Crude peptide is purified by preparative reversed-phase HPLC: the mixture is pushed through a column and the fractions containing the target are collected. It is effective and it is where a large part of the cost lives, because purity is bought by throwing material away.
The purity figure on a certificate is normally an area percentage from an analytical HPLC trace at a single wavelength. Read literally, it says: of the material this method detected, this proportion eluted in the main peak. It does not say:
- that co-eluting impurities were resolved — an epimer often is not;
- anything about substances the detector does not see at that wavelength;
- anything about water, residual solvent or counterion content;
- anything about endotoxin, bioburden or sterility.
A vial can be 99% pure by area and still be mostly not peptide by mass.
Peptide content: the number that tells you what you bought
After purification the material is lyophilised — frozen and dried under vacuum, leaving the cake you see in the vial. What remains is peptide plus residual water plus counterion.
Net peptide content is the fraction of the powder that is actually peptide, and it is commonly well below 100%. A vial labelled 5 mg may contain meaningfully less than 5 mg of peptide, entirely legitimately, if the label refers to gross powder mass. Two suppliers quoting the same milligrams and the same purity can be selling materially different amounts of the active substance.
If a certificate reports purity but not net peptide content, you cannot compute what you have.
Fill, finish and sterility — where the real risk is
Everything so far concerns identity and potency. Injection introduces a different class of risk, and it is the one that hurts patients.
- Sterility is not a property of a clean-looking powder. It is the outcome of a validated aseptic process or terminal sterilisation, plus testing.
- Bacterial endotoxin survives sterilisation. Dead organisms still pyrogenic. It is tested for separately and has limits based on dose and route.
- Particulates and container closure integrity matter for an injectable and are routinely absent from gray-market documentation.
- Reconstitution happens outside anyone’s quality system. Bacteriostatic water contains a preservative — commonly 0.9% benzyl alcohol — and sterile water does not; the choice changes how long a reconstituted vial can be used and, in some populations, whether the preservative is appropriate at all.
In a lawful supply chain, sterile preparation is governed — USP compounding standards for a 503A pharmacy, CGMP for a 503B outsourcing facility. In the gray market it is governed by whoever was holding the vial.
Reading a certificate of analysis properly
| Line item | What it establishes | What it does not |
|---|---|---|
| Mass spectrometry | The molecular weight is consistent with the sequence | Stereochemistry; identity against an epimer |
| HPLC purity (area %) | Proportion of detected material in the main peak | Co-eluting impurities; anything invisible at that wavelength |
| Net peptide content | How much of the powder is peptide | Nothing about safety |
| Water / residual solvent | What else is in the cake | Sterility |
| Endotoxin, sterility | Suitability for injection | Identity or potency |
| Counterion | TFA versus acetate salt form | Whether a salt exchange was performed properly |
And the meta-question that outranks all of them: who signed it, and did they test this batch? A certificate carrying no batch number, no method references, no date and no accredited laboratory is a design file, not a test result.
Why this is a business question, not a chemistry question
Two vials, same sequence, same stated purity, ten-fold price difference. The gap is not margin. It is coupling efficiency, purification yield, salt exchange, analytical method development, stability data, aseptic fill, endotoxin testing and a quality system that can produce the same result twice. You are not comparing products. You are comparing process control, and the certificate is the only window you get.
Which is why the sourcing question — covered in imported API versus US CGMP — is really a question about whose quality system stands behind the vial.
Where MDside sits
The practices we support source through licensed pharmacies whose authority we confirm in writing, and we look at the documentation rather than the price list. A substance with no completed regulatory pathway does not get on the formulary regardless of how good the certificate looks.
See how our peptide programs are structured, or read 503A versus 503B sourcing.
Related reading
Frequently asked questions
How are peptides manufactured?
Short peptides are usually built by solid-phase synthesis: the chain is assembled one amino acid at a time on a resin, cleaved, purified by reversed-phase HPLC, converted to an appropriate salt and lyophilised. Larger therapeutic peptides are more often produced recombinantly.
Does 99% purity mean the vial is 99% peptide?
No. Purity is normally an HPLC area percentage describing detected material. Net peptide content — the proportion of the powder that is actually peptide, after water and counterion — is a separate number and is commonly well below 100%.
What is the TFA salt problem?
Synthesised peptides are typically isolated as trifluoroacetate salts. TFA is an undesirable counterion for administration and a confounder in cell work, so conversion to a salt such as acetate is an extra deliberate step that a cost-driven supplier may omit.
Can a mass spec result confirm a peptide is what it claims to be?
Only partly. Mass spectrometry confirms molecular weight is consistent with the sequence. It cannot distinguish a stereoisomer of identical mass, and it says nothing about sterility, endotoxin or potency.
What makes an injectable peptide safe to inject?
Not the powder’s appearance. Sterility from a validated aseptic or terminal process, endotoxin within limits for the dose and route, container closure integrity, and appropriate reconstitution and beyond-use dating — each tested and documented, not assumed.
General technical information about peptide manufacture and quality testing. Not clinical, legal or engineering advice, and not a substitute for a qualified quality assessment of a specific supplier or batch.